FundedIQ
Biotechnology

Tafalgie Therapeutics: Funding, Investors & Team (Sep 2026)

Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.

tafalgie.fr LinkedIn Marseille, France 11-50 employees
Total raised
$14.1M
Rounds
1
Latest
Series A
Sep 2025

Tafalgie Therapeutics has raised $14.1M across 1 funding round on record, the most recent a Series A of $14.1M announced in Sep 2025.

That round is below the $21M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Tafalgie Therapeutics Company Profile and Key Stats

Total funding raised
$14.1M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$14.1M in Sep 2025
Employees
11-50
reported band
Headquarters
Marseille, France

Latest funding round on record: Sep 2025.

Tafalgie Therapeutics Funding Rounds

Date
Round
Amount
Series A
$14.1M

Tafalgie Therapeutics Founders and Leadership Team

Name
Role
Contact
Éric Schettini
Locked

Contact details for the Tafalgie Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.

Start 14-day free trial →

Tafalgie Therapeutics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
1,705
$6.7M
8,352
$15M

Tafalgie Therapeutics' latest round of $14.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Tafalgie Therapeutics in Biotechnology and Marseille

Companies Similar to Tafalgie Therapeutics

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates…

Series A $122M

AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other…

Series C $120M

Ollin Biosciences operates as a clinical-stage biopharmaceutical company.

Series B $330M

Dayra Therapeutics manufactures peptide based medicines.

Undisclosed round $20.0M

4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment…

Series C $35.9M

Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and…

Series C $56.2M

Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary…

Series B $9.8M

Brise Pharma operates in the scientific research and technical service industry.

Series A $28.1M

Vybio is a high-tech enterprise focusing on innovative drug research and development.

Series B $14.1M

Chirality Biosciences is a developer of chiral molecule separation technology enabling faster, safer, and…

Pre-Seed $3.1M

Bexorg provides a technology platform for central nervous system drug discovery and development.

Series A $23.0M

AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.

Series A $21.0M

Tafalgie Therapeutics Funding FAQs

What does Tafalgie Therapeutics do?

Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.

How much funding has Tafalgie Therapeutics raised?

Tafalgie Therapeutics has raised $14.1M across 1 round on record. The most recent is a Series A of $14.1M announced in Sep 2025.

When did Tafalgie Therapeutics last raise funding?

Tafalgie Therapeutics' most recent funding round on record is a Series A of $14.1M, announced in Sep 2025.

Where is Tafalgie Therapeutics headquartered?

Tafalgie Therapeutics is based in Marseille, France.

How many employees does Tafalgie Therapeutics have?

Tafalgie Therapeutics is in the 11-50 employee band.

How does Tafalgie Therapeutics' funding compare to other Biotechnology startups?

Tafalgie Therapeutics' latest round of $14.1M is below the $21M median round size for Biotechnology companies on FundedIQ across 29 tracked companies over the last two years.

About FundedIQ's Tafalgie Therapeutics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tafalgie Therapeutics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.